Cargando…
Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
The clinical and immune modulatory effects of interleukin-2 (IL-2) and interferon (INF) alfa-2a were examined in a phase II study in patients with metastatic renal cell carcinoma (six patients) and melanoma (eight patients). Treatment consisted in IL-2 3 MU/m2 continuous infusion days 1-4 and INF al...
Autores principales: | Pichert, G., Jost, L. M., Fierz, W., Stahel, R. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971775/ https://www.ncbi.nlm.nih.gov/pubmed/1997108 |
Ejemplares similares
-
Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.
por: Pichert, G., et al.
Publicado: (1990) -
Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
por: Jia, Dong-Dong, et al.
Publicado: (2021) -
Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.
por: Kruit, W. H., et al.
Publicado: (1995) -
Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
por: Fiorentino, B., et al.
Publicado: (1992) -
Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?
por: Hauschild, A.
Publicado: (2009)